- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00447551
Canadian Aesthetic Experience With Sculptra Therapy
Canadian Study of the Use of Injectable POLY-L-LACTIC Acid (Sculptra Therapy) in Aesthetic Medicine
Primary objective To evaluate the degree of correction achievable with Sculptra for nasolabial folds, mid- and lower facial volume loss, jawline laxity and other signs of facial ageing.
To document the types and incidence of device-related adverse events with Sculptra.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Québec, Canada
- Sanofi-Aventis Administrative Office
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Present with nasolabial folds, mid- and lower facial volume loss, jawline laxity or other signs of facial ageing to be treated with Sculptra
- The subject must be willing and able to provide written informed consent that includes a release for use of their photographs in publications. Subjects who refuse the photo release will not be eligible to participate in the study.
- Female subjects must be post-menopausal for at least one year or have had a hysterectomy or tubal ligation; if of child-bearing potential, must agree to use an approved method of birth control throughout the study (i.e., oral/systemic contraceptives, intrauterine device (IUD), or spermicide in combination with a barrier method of contraception);
Exclusion Criteria:
- Personal history of allergic/anaphylactic reactions, including hypersensitivity to local anaesthetics (lidocaine);
- Known history of bleeding disorders;
- Active inflammatory process in the area to be treated (skin eruptions such as cysts, pimples, rashes, cancerous/pre-cancerous lesions, or any other active skin disease);
- Active hepatitis within the past year;
- Subjects who are pregnant or who plan to become pregnant within the study timeframe, or who are breastfeeding;
- HIV positive patients;
- Recent history of trauma in the face (< 1 year);
- Previous use of Dermalive or Dermadeep;
- Previous facial surgery within the last six months;
- Recent facial filler within the last six months;
- Planned surgical interventions (such as rhinoplasty, facelift, congenital defect repair) or use of other fillers or lasers for the initial six months post-Sculptra therapy;
- Subjects with clinically important disease as judged by the investigator within 3 months of the start of the study (e.g., history of significant lab abnormalities, myocardial infarct, stroke, cancer, connective tissue disease, etc.), including subjects with medical conditions that might require the use of immunosuppressive medications during the trial (severe asthma, rheumatoid arthritis, organ transplant, etc.);
- Subjects who have used superficial dermal resurfacing procedures in the facial area, including chemical peel, dermabrasion, or microderm treatments within six weeks of visit 1 and for the duration of the main study.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single group
|
Deep dermal injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the degree of correction attainable with Sculptra (injectable PLLA) for the correction of nasolabial folds, mid-and lower facial volume loss, jawline laxicity, and other signs of facial aging.
Time Frame: From baseline to 6-months post-Sculptra therapy
|
From baseline to 6-months post-Sculptra therapy
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Document the types and incidence of device adverse events with Sculptra Therapy (Injectable PLLA)
Time Frame: From baseline to 6-months post-Sculptra therapy
|
From baseline to 6-months post-Sculptra therapy
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Mary Tzortzis, Sanofi
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- POLYL_L_01777
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Aging
-
Amazentis SAproDERM GmbHCompleted
-
Endymion Medical LtdCompleted
-
Endymion Medical LtdCompletedSkin Aging | Skin WrinklingIsrael
-
BioibericaRecruiting
-
Crown Laboratories, Inc.Completed
-
HugelCompletedSkin AgingKorea, Republic of
-
Technological Centre of Nutrition and Health, SpainUniversity Rovira i Virgili; Hospital Universitari Sant Joan de Reus; Fundació... and other collaboratorsCompleted
-
Medy-ToxCompletedSkin AgingKorea, Republic of
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Revance Therapeutics, Inc.Completed
Clinical Trials on Poly-L-Lactic Acid
-
Galderma R&DCompletedWrinkles in DecolletageUnited States
-
Galderma Brasil Ltda.Completed
-
Bausch Health Americas, Inc.Completed
-
Bausch Health Americas, Inc.CompletedFacial LipoatrophyUnited States
-
Bausch Health Americas, Inc.CompletedNasolabial Fold WrinklesUnited States
-
Bausch Health Americas, Inc.CompletedNasolabial Fold WrinklesUnited States
-
Erevna Innovations Inc.Completed
-
Bausch Health Americas, Inc.Completed
-
Bausch Health Americas, Inc.CompletedMid Facial Contour DeficienciesUnited Kingdom
-
UMC UtrechtTerminatedHead and Neck Neoplasms | RadioisotopesNetherlands